A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy

Sistonen, Johanna; Smith, Chingying; Fu, Yung-Kang; Largiadèr, Carlo R (2012). A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy. Clinica chimica acta, 414, pp. 109-111. Amsterdam: Elsevier 10.1016/j.cca.2012.08.015

Full text not available from this repository. (Request a copy)

Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe toxicity. Recently described genetic variation in dihydropyrimidine dehydrogenase (DPYD) has been shown to be a major predictor of 5FU toxicity. Here, we describe a new genotyping assay for routine clinical use that covers all the major DPYD risk variants.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Sistonen, Johanna and Largiadèr, Carlo Rodolfo

ISSN:

0009-8981

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:36

Last Modified:

08 Jun 2016 10:31

Publisher DOI:

10.1016/j.cca.2012.08.015

PubMed ID:

22935545

Web of Science ID:

000312685400023

URI:

https://boris.unibe.ch/id/eprint/14663 (FactScience: 221745)

Actions (login required)

Edit item Edit item
Provide Feedback